Alnylam (ALNY) CCO receives 1,666 shares from RSU vesting

Rhea-AI Filing Summary

Alnylam Pharmaceuticals executive Tolga Tanguler acquired shares through equity compensation. On February 27, 2026, 1,666 restricted stock units were exercised at $0.00 per share and converted into 1,666 shares of common stock, increasing his directly held stake to 33,435 shares.

These RSUs were part of a 5,000-unit grant awarded on February 27, 2023 under the company’s Amended and Restated 2018 Stock Incentive Plan. The award vested in three equal annual installments, and this filing reflects the third and final tranche becoming fully vested and released.

Insider Trade Summary

1,666 shares exercised/converted

Mixed 2 txns

Insider Tanguler Tolga

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,666	$0.00	--
Exercise	Common Stock	1,666	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 33,435 shares (Direct)

Footnotes (1)

1. These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tanguler Tolga

(Last) (First) (Middle)

675 WEST KENDALL STREET

HENRI A. TERMEER SQUARE

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		M		1,666	A	$0.0	33,435	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/27/2026		M			1,666	(2)	(3)	Common Stock	1,666	$0.0	0	D

Explanation of Responses:

1. These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock.

2. On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

3. The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.

	By: Brett Budzinski, Attorney-in-Fact For: Tolga Tanguler	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Alnylam (ALNY) executive Tolga Tanguler report in this Form 4?

Tolga Tanguler reported the vesting and exercise of 1,666 restricted stock units into 1,666 shares of Alnylam common stock. The transaction stems from an equity award granted in 2023 and reflects routine compensation rather than an open-market stock purchase or sale.

How many Alnylam (ALNY) shares does Tolga Tanguler own after this transaction?

After the RSU conversion, Tolga Tanguler directly owns 33,435 shares of Alnylam common stock. This total reflects the addition of 1,666 shares from the February 27, 2026 vesting event, which was the final tranche of his February 27, 2023 restricted stock unit grant.

What equity award is disclosed in this Alnylam (ALNY) Form 4 filing?

The filing discloses a restricted stock unit grant of 5,000 units made on February 27, 2023. These RSUs vest in three equal annual installments, with one-third vesting on each anniversary date. The February 27, 2026 transaction represents the third and final vesting tranche.

Was there any cash paid in Tolga Tanguler’s Alnylam (ALNY) RSU exercise?

No cash changed hands in this RSU exercise; the transaction price per share was reported as $0.00. The filing reflects a conversion of 1,666 restricted stock units into common shares as part of a previously granted equity award under Alnylam’s 2018 Stock Incentive Plan.

Is this Alnylam (ALNY) Form 4 transaction a stock sale by Tolga Tanguler?

The transaction is not a stock sale. It is categorized as an exercise or conversion of a derivative security, where 1,666 restricted stock units converted into 1,666 common shares. Tolga Tanguler’s reported direction is “acquire,” increasing his directly held Alnylam share ownership.